Gaurav Syal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gaurav Syal has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Gil Y Melmed
F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
3 shared publications- Gil Y. Melmed
Inflammatory Bowel and Immunobiology Research Institute, Karsh Division of Digestive and Liver Diseases, Cedars-Sinai, Los Angeles, California, USA
3 shared publications Phillip R Fleshner
Department of Surgery, Cedars-Sinai Medical Center , Los Angeles, CA
3 shared publicationsAmir Kashani
Division of Gastroenterology, Department of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, Calif
2 shared publications- Dermot PB McGovern
F. Widjaja Inflammatory Bowel Disease Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
2 shared publications - Matthew A. Ciorba
Inflammatory Bowel Diseases Center, Division of Gastroenterology, Department of Medicine, Washington University School of Medicine, St. Louis, USA
2 shared publications
Latest Publications
- 16 October 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (1) , 135-150
Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders—A Systematic Review and Meta-Analysis
INTRODUCTION: Pouchitis and Crohn's-like disease of the pouch (CLDP) are common in patients who undergo ileal pouch anal anastomosis for ulcerative colitis. We conducted separate systematic reviews to evaluate the effectiveness of available interventions to prevent and treat pouchitis and CLDP. METHODS: Through systematic literature reviews, we identified studies that evaluated the effectiveness of probiotics, antibiotics, 5-aminosalicylates, nonsystemic oral corticosteroids, and advanced therapies for prevention and treatment of pouchitis and CLDP for meta-analysis. Primary outcomes were occurrence of pouchitis for pouchitis prevention and clinical response for pouchitis and CLDP treatment. We estimated the relative effectiveness of these interventions using the existing placebo response rates or hypothetical spontaneous improvement rates derived from clinical trials of pouchitis, ulcerative colitis, and Crohn's disease. RESULTS: Probiotics were effective for primary (relative risk [RR] 0.18; 95% confidence interval [CI] 0.05–0.62) and secondary prevention (RR 0.17; 95% CI 0.09–0.34) of pouchitis. Antibiotics were effective for treatment of acute and chronic pouchitis (12 cohorts; RR 1.67; 95% CI 1.34–2.01; response rate 65%; 95% CI 52–75) with ciprofloxacin and metronidazole-based regimens being more effective than rifaximin. Advanced therapies were effective for treatment of chronic antibiotic-refractory pouchitis (31 cohorts; RR 1.71; 95% CI 1.28–2.56; response rate 50%; 95% CI 43–57) and CLDP (10 cohorts; RR 2.49; 95% CI 1.87–3.73; response rate 74%; 95% CI 68–79) without significant difference between classes. DISCUSSION: Multiple medical interventions are effective for prevention and treatment of pouchitis and CLDP. Given the overall low quality of data, further research is needed to confirm these findings.
- 16 October 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (1) , 135-150
Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders—A Systematic Review and Meta-Analysis
INTRODUCTION: Pouchitis and Crohn's-like disease of the pouch (CLDP) are common in patients who undergo ileal pouch anal anastomosis for ulcerative colitis. We conducted separate systematic reviews to evaluate the effectiveness of available interventions to prevent and treat pouchitis and CLDP. METHODS: Through systematic literature reviews, we identified studies that evaluated the effectiveness of probiotics, antibiotics, 5-aminosalicylates, nonsystemic oral corticosteroids, and advanced therapies for prevention and treatment of pouchitis and CLDP for meta-analysis. Primary outcomes were occurrence of pouchitis for pouchitis prevention and clinical response for pouchitis and CLDP treatment. We estimated the relative effectiveness of these interventions using the existing placebo response rates or hypothetical spontaneous improvement rates derived from clinical trials of pouchitis, ulcerative colitis, and Crohn's disease. RESULTS: Probiotics were effective for primary (relative risk [RR] 0.18; 95% confidence interval [CI] 0.05–0.62) and secondary prevention (RR 0.17; 95% CI 0.09–0.34) of pouchitis. Antibiotics were effective for treatment of acute and chronic pouchitis (12 cohorts; RR 1.67; 95% CI 1.34–2.01; response rate 65%; 95% CI 52–75) with ciprofloxacin and metronidazole-based regimens being more effective than rifaximin. Advanced therapies were effective for treatment of chronic antibiotic-refractory pouchitis (31 cohorts; RR 1.71; 95% CI 1.28–2.56; response rate 50%; 95% CI 43–57) and CLDP (10 cohorts; RR 2.49; 95% CI 1.87–3.73; response rate 74%; 95% CI 68–79) without significant difference between classes. DISCUSSION: Multiple medical interventions are effective for prevention and treatment of pouchitis and CLDP. Given the overall low quality of data, further research is needed to confirm these findings.
- 3 October 2023
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 30 (10) , 1907-1910
Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study
Chronic pouchitis develops in 10% to 20% of patients who undergo total proctocolectomy with ileal–pouch anal anastomosis (IPAA) for ulcerative colitis (UC).1 It is associated with poor quality of life and an increased risk of pouch failure.2 Unfortunately, the treatment options for this condition are limited to chronic antibiotics that are effective in a subset of these patients biologic drugs that are only modestly effective, and more recently vedolizumab.1,3 Tofacitinib is an oral Janus kinase (JAK) inhibitor approved for treatment of adults with UC.4 Increased mucosal expression of STAT (signal transducer and activator of transcription)-1 and its normalization with antibiotic therapy has been reported in patients with pouchitis and provides biologic plausibility to the effectiveness of JAK-STAT signaling pathway blockade in chronic pouchitis.5 We aimed to evaluate the efficacy and safety of tofacitinib for the treatment of chronic pouchitis in a prospective, open-label pilot study. Adults with UC who underwent IPAA surgery and were subsequently diagnosed with chronic pouchitis were prospectively enrolled in this 8-week pilot study at Cedars-Sinai Medical Center between January 2021 and June 2022. Chronic active pouchitis was defined as a modified Pouchitis Disease Activity Index (mPDAI) ≥5 with a minimum endoscopic subscore of 2 with ≥3 episodes of pouchitis within the preceding 1 year or pouchitis treated with continuous antibiotics for ≥4 weeks. Patients with perianal disease and/or nonanastomotic strictures in the ileal pouch or prepouch ileum were excluded. Stable doses of antibiotics and corticosteroids (≤20 mg prednisone dose equivalent) were permitted without dose adjustment during the study period. Concomitant immunomodulator therapy was not allowed. Eligible patients received oral tofacitinib 10 mg twice daily for 8 weeks, with scheduled visits at weeks 4 and 8. At each study visit, patients submitted a symptom diary and underwent a physical exam, laboratory studies, and fecal calprotectin (FCP) testing. All patients underwent centrally read pouchoscopy at baseline and week 8. The primary outcome was response at 8 weeks, defined as ≥2-point decrease in mPDAI from baseline with at least 1-point decrease in endoscopic subscore. Secondary outcomes included remission defined as mPDAI <5 with a ≥2-point decrease from baseline and changes in clinical and endoscopic PDAI subscores, FCP, and the 10-point Cleveland Global Quality of Life (CGQL) scores at 8 weeks.
- 3 October 2023
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 30 (10) , 1907-1910
Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study
Chronic pouchitis develops in 10% to 20% of patients who undergo total proctocolectomy with ileal–pouch anal anastomosis (IPAA) for ulcerative colitis (UC).1 It is associated with poor quality of life and an increased risk of pouch failure.2 Unfortunately, the treatment options for this condition are limited to chronic antibiotics that are effective in a subset of these patients biologic drugs that are only modestly effective, and more recently vedolizumab.1,3 Tofacitinib is an oral Janus kinase (JAK) inhibitor approved for treatment of adults with UC.4 Increased mucosal expression of STAT (signal transducer and activator of transcription)-1 and its normalization with antibiotic therapy has been reported in patients with pouchitis and provides biologic plausibility to the effectiveness of JAK-STAT signaling pathway blockade in chronic pouchitis.5 We aimed to evaluate the efficacy and safety of tofacitinib for the treatment of chronic pouchitis in a prospective, open-label pilot study. Adults with UC who underwent IPAA surgery and were subsequently diagnosed with chronic pouchitis were prospectively enrolled in this 8-week pilot study at Cedars-Sinai Medical Center between January 2021 and June 2022. Chronic active pouchitis was defined as a modified Pouchitis Disease Activity Index (mPDAI) ≥5 with a minimum endoscopic subscore of 2 with ≥3 episodes of pouchitis within the preceding 1 year or pouchitis treated with continuous antibiotics for ≥4 weeks. Patients with perianal disease and/or nonanastomotic strictures in the ileal pouch or prepouch ileum were excluded. Stable doses of antibiotics and corticosteroids (≤20 mg prednisone dose equivalent) were permitted without dose adjustment during the study period. Concomitant immunomodulator therapy was not allowed. Eligible patients received oral tofacitinib 10 mg twice daily for 8 weeks, with scheduled visits at weeks 4 and 8. At each study visit, patients submitted a symptom diary and underwent a physical exam, laboratory studies, and fecal calprotectin (FCP) testing. All patients underwent centrally read pouchoscopy at baseline and week 8. The primary outcome was response at 8 weeks, defined as ≥2-point decrease in mPDAI from baseline with at least 1-point decrease in endoscopic subscore. Secondary outcomes included remission defined as mPDAI <5 with a ≥2-point decrease from baseline and changes in clinical and endoscopic PDAI subscores, FCP, and the 10-point Cleveland Global Quality of Life (CGQL) scores at 8 weeks.
- 13 December 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (2) , 404-413
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn’s Disease in Remission on Infliximab and Azathioprine
Background In Crohn’s disease, combination therapy with infliximab and azathioprine is more effective than either drug alone but is associated with a higher risk of therapy-related complications. Though therapy de-escalation can reduce risks and save costs, it is associated with a risk of Crohn’s disease relapse. Aims We aimed to study the cost-effectiveness of de-escalation strategies in Crohn’s disease patients in remission on infliximab and azathioprine. Methods We constructed a decision tree with Markov models for continuation of infliximab and azathioprine, discontinuation of azathioprine followed by its re-introduction in case of relapse, discontinuation of azathioprine followed by infliximab dose intensification without azathioprine reintroduction in case of relapse and discontinuation of infliximab. Third-party payers’ perspective with a willingness-to-pay threshold of $100,000/quality-adjusted life years was used. Markov cycle length was 3 months, and the study period was 5 years. A 35-year-old patient with Crohn’s disease in clinical remission on azathioprine 150 mg daily and infliximab 5 mg/kg every 8 weeks was used for base-case analysis. Results Azathioprine withdrawal followed by its reintroduction upon relapse was the dominant strategy as it was the most effective and least expensive approach on base-case analysis. It was also cost-effective in 99.3% of Monte Carlo trial simulations. AZA withdrawal without IFX dose intensification upon relapse was the least effective and the most expensive strategy. Conclusion Azathioprine withdrawal is the most effective and least costly de-escalation strategy in CD patients in remission on combination therapy if AZA re-introduction is performed upon CD relapse.
- 13 December 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (2) , 404-413
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn’s Disease in Remission on Infliximab and Azathioprine
Background In Crohn’s disease, combination therapy with infliximab and azathioprine is more effective than either drug alone but is associated with a higher risk of therapy-related complications. Though therapy de-escalation can reduce risks and save costs, it is associated with a risk of Crohn’s disease relapse. Aims We aimed to study the cost-effectiveness of de-escalation strategies in Crohn’s disease patients in remission on infliximab and azathioprine. Methods We constructed a decision tree with Markov models for continuation of infliximab and azathioprine, discontinuation of azathioprine followed by its re-introduction in case of relapse, discontinuation of azathioprine followed by infliximab dose intensification without azathioprine reintroduction in case of relapse and discontinuation of infliximab. Third-party payers’ perspective with a willingness-to-pay threshold of $100,000/quality-adjusted life years was used. Markov cycle length was 3 months, and the study period was 5 years. A 35-year-old patient with Crohn’s disease in clinical remission on azathioprine 150 mg daily and infliximab 5 mg/kg every 8 weeks was used for base-case analysis. Results Azathioprine withdrawal followed by its reintroduction upon relapse was the dominant strategy as it was the most effective and least expensive approach on base-case analysis. It was also cost-effective in 99.3% of Monte Carlo trial simulations. AZA withdrawal without IFX dose intensification upon relapse was the least effective and the most expensive strategy. Conclusion Azathioprine withdrawal is the most effective and least costly de-escalation strategy in CD patients in remission on combination therapy if AZA re-introduction is performed upon CD relapse.
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
337: PANETH CELL PHENOTYPE AT ILEAL RESECTION MARGIN OBTAINED AT TIME OF ILEOCOLECTOMY FOR ULCERATIVE COLITIS CORRELATES WITH POUCH COMPLICATIONS
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
337: PANETH CELL PHENOTYPE AT ILEAL RESECTION MARGIN OBTAINED AT TIME OF ILEOCOLECTOMY FOR ULCERATIVE COLITIS CORRELATES WITH POUCH COMPLICATIONS
- 10 January 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (10) , 4687-4694
Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology
Background and Aims The treatment of chronic pouchitis remains a challenge due to the paucity of high-quality studies. We aimed to provide guidance for clinicians on the appropriateness of medical and surgical treatments in chronic pouchitis. Methods Appropriateness of medical and surgical treatments in patients with chronic pouchitis was considered in 16 scenarios incorporating presence/absence of four variables: pouchitis symptoms, response to antibiotics, significant prepouch ileitis, and Crohn’s disease (CD)-like complications (i.e., stricture or fistula). Appropriateness of permanent ileostomy in patients refractory to medical treatments was considered in eight additional scenarios. Using the RAND/UCLA appropriateness method, international IBD expert panelists rated appropriateness of treatments in each scenario on a 1–9 scale. Results Chronic antibiotic therapy was rated appropriate only in asymptomatic antibiotic-dependent patients with no CD-like complications and inappropriate in all other scenarios. Ileal-release budesonide was rated appropriate in 6/16 scenarios including patients with significant prepouch ileitis but no CD-like complications. Probiotics were considered either inappropriate (14/16) or uncertain (2/16). Biologic therapy was considered appropriate in most scenarios (14/16) and uncertain in situations where significant prepouch ileitis or CD-like complications were absent (2/16). In patients who are refractory to all medications, permanent ileostomy was considered appropriate in all scenarios (7/8) except in asymptomatic patients with no CD-like complications. Conclusions In the presence of significant prepouch ileitis or CD-like complications, chronic antibiotics and probiotics are inappropriate. Biologics are appropriate in all patients except in asymptomatic patients with no evidence of complications. Permanent ileostomy is appropriate in most medically refractory patients.
- 10 January 2022
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (10) , 4687-4694
Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology
Background and Aims The treatment of chronic pouchitis remains a challenge due to the paucity of high-quality studies. We aimed to provide guidance for clinicians on the appropriateness of medical and surgical treatments in chronic pouchitis. Methods Appropriateness of medical and surgical treatments in patients with chronic pouchitis was considered in 16 scenarios incorporating presence/absence of four variables: pouchitis symptoms, response to antibiotics, significant prepouch ileitis, and Crohn’s disease (CD)-like complications (i.e., stricture or fistula). Appropriateness of permanent ileostomy in patients refractory to medical treatments was considered in eight additional scenarios. Using the RAND/UCLA appropriateness method, international IBD expert panelists rated appropriateness of treatments in each scenario on a 1–9 scale. Results Chronic antibiotic therapy was rated appropriate only in asymptomatic antibiotic-dependent patients with no CD-like complications and inappropriate in all other scenarios. Ileal-release budesonide was rated appropriate in 6/16 scenarios including patients with significant prepouch ileitis but no CD-like complications. Probiotics were considered either inappropriate (14/16) or uncertain (2/16). Biologic therapy was considered appropriate in most scenarios (14/16) and uncertain in situations where significant prepouch ileitis or CD-like complications were absent (2/16). In patients who are refractory to all medications, permanent ileostomy was considered appropriate in all scenarios (7/8) except in asymptomatic patients with no CD-like complications. Conclusions In the presence of significant prepouch ileitis or CD-like complications, chronic antibiotics and probiotics are inappropriate. Biologics are appropriate in all patients except in asymptomatic patients with no evidence of complications. Permanent ileostomy is appropriate in most medically refractory patients.
- 1 September 2021
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 6 (9) , 690-691
Endoscopic evaluation after surgery in inflammatory bowel disease
- 1 September 2021
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 6 (9) , 690-691
Endoscopic evaluation after surgery in inflammatory bowel disease
- Open Access
- 10 December 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (6) , 960-968
Pre-pouch Ileitis is Associated with Development of Crohn’s Disease-like Complications and Pouch Failure
It is unclear whether pre-pouch ileitis heralds an aggressive inflammatory pouch disease in patients with ileal pouch-anal anastomosis [IPAA]. We compared outcomes of patients with pouchitis and concomitant pre-pouch ileitis with those with pouchitis alone. Patients undergoing IPAA surgery for inflammatory bowel disease, who subsequently developed pouchitis with concomitant pre-pouch ileitis [pre-pouch ileitis group], were matched by year of IPAA surgery and preoperative diagnosis [ulcerative colitis or inflammatory bowel disease-unclassified] with patients who developed pouchitis alone [pouchitis group]. Primary outcomes were development of Crohn’s disease [CD]-like complications [non-anastomotic strictures or perianal disease >6 months after ileostomy closure] and pouch failure. Secondary outcomes were need for surgical/endoscopic interventions and immunosuppressive therapy. Log-rank testing was used to compare outcome-free survival, and Cox regression was performed to identify predictors of outcomes. There were 66 patients in each group. CD-like complications and pouch failure developed in 36.4% and 7.6% patients in the pre-pouch ileitis group and 10.6% and 1.5% in pouchitis group, respectively. CD-like complications-free survival [log-rank p = 0.0002] and pouch failure-free survival [log-rank p = 0.046] were significantly lower in the pre-pouch ileitis group. The pre-pouch ileitis group had a higher risk of requiring surgical/endoscopic interventions [log-rank p = 0.0005] and immunosuppressive therapy [log-rank p p = 0.0007), need for surgical/endoscopic interventions [HR 4.1; p = 0.002], and immunosuppressive therapy [HR 5.0; p = 0.0002]. Pre-pouch ileitis is associated with a higher risk of complicated disease and pouch failure than pouchitis. It should be considered a feature of CD.
- 10 December 2020
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 15 (6) , 960-968
Open AccessPre-pouch Ileitis is Associated with Development of Crohn’s Disease-like Complications and Pouch Failure
It is unclear whether pre-pouch ileitis heralds an aggressive inflammatory pouch disease in patients with ileal pouch-anal anastomosis [IPAA]. We compared outcomes of patients with pouchitis and concomitant pre-pouch ileitis with those with pouchitis alone. Patients undergoing IPAA surgery for inflammatory bowel disease, who subsequently developed pouchitis with concomitant pre-pouch ileitis [pre-pouch ileitis group], were matched by year of IPAA surgery and preoperative diagnosis [ulcerative colitis or inflammatory bowel disease-unclassified] with patients who developed pouchitis alone [pouchitis group]. Primary outcomes were development of Crohn’s disease [CD]-like complications [non-anastomotic strictures or perianal disease >6 months after ileostomy closure] and pouch failure. Secondary outcomes were need for surgical/endoscopic interventions and immunosuppressive therapy. Log-rank testing was used to compare outcome-free survival, and Cox regression was performed to identify predictors of outcomes. There were 66 patients in each group. CD-like complications and pouch failure developed in 36.4% and 7.6% patients in the pre-pouch ileitis group and 10.6% and 1.5% in pouchitis group, respectively. CD-like complications-free survival [log-rank p = 0.0002] and pouch failure-free survival [log-rank p = 0.046] were significantly lower in the pre-pouch ileitis group. The pre-pouch ileitis group had a higher risk of requiring surgical/endoscopic interventions [log-rank p = 0.0005] and immunosuppressive therapy [log-rank p p = 0.0007), need for surgical/endoscopic interventions [HR 4.1; p = 0.002], and immunosuppressive therapy [HR 5.0; p = 0.0002]. Pre-pouch ileitis is associated with a higher risk of complicated disease and pouch failure than pouchitis. It should be considered a feature of CD.
- 13 March 2020
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (1) , 199-205
Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative Colitis
Background and Aims Infliximab rescue therapy is effective in patients with corticosteroid refractory acute severe ulcerative colitis, but predictors of response remain poorly understood. We aimed to identify predictors of colectomy in this high-risk patient population. Methods Patients hospitalized with acute severe ulcerative colitis who received infliximab after failing intravenous corticosteroid therapy between July 2012 and June 2017 were retrospectively identified. Stepwise regression with backward elimination was used to identify predictors of colectomy at 90 days and 1 year. Ninety-day and 1-year colectomy rates were compared between the patients who received 5 mg/kg and 10 mg/kg IFX rescue dose. Results Sixty-three patients met the eligibility criteria. Twenty-nine patients received 5 mg/kg, and 34 received 10 mg/kg infliximab dose. Serum albumin on admission (OR 0.10; p = 0.04) and band neutrophil percentage at the time of infliximab administration (OR 1.21; p = 0.02) were independent predictors of 90-day colectomy. A combination of serum albumin ≤ 2.5 g/dl and band neutrophil count ≥ 13% had a 100% positive predictive value for 90-day colectomy. Unadjusted 90-day and 1-year colectomy rates were similar in the 5 mg/kg and 10 mg/kg infliximab groups. After adjusting for confounding factors, 10 mg/kg infliximab dose was potentially protective for 90-day (OR 0.07; p = 0.06) but not for 1-year colectomy (OR 0.19; p = 0.16). Conclusions Bandemia and low serum albumin are independent predictors of failure of infliximab rescue therapy in acute severe ulcerative colitis. Serum albumin ≤ 2.5 g/dl and band neutrophil count ≥ 13% had a 100% positive predictive value for 90-day colectomy.
- 13 March 2020
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 66 (1) , 199-205
Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative Colitis
Background and Aims Infliximab rescue therapy is effective in patients with corticosteroid refractory acute severe ulcerative colitis, but predictors of response remain poorly understood. We aimed to identify predictors of colectomy in this high-risk patient population. Methods Patients hospitalized with acute severe ulcerative colitis who received infliximab after failing intravenous corticosteroid therapy between July 2012 and June 2017 were retrospectively identified. Stepwise regression with backward elimination was used to identify predictors of colectomy at 90 days and 1 year. Ninety-day and 1-year colectomy rates were compared between the patients who received 5 mg/kg and 10 mg/kg IFX rescue dose. Results Sixty-three patients met the eligibility criteria. Twenty-nine patients received 5 mg/kg, and 34 received 10 mg/kg infliximab dose. Serum albumin on admission (OR 0.10; p = 0.04) and band neutrophil percentage at the time of infliximab administration (OR 1.21; p = 0.02) were independent predictors of 90-day colectomy. A combination of serum albumin ≤ 2.5 g/dl and band neutrophil count ≥ 13% had a 100% positive predictive value for 90-day colectomy. Unadjusted 90-day and 1-year colectomy rates were similar in the 5 mg/kg and 10 mg/kg infliximab groups. After adjusting for confounding factors, 10 mg/kg infliximab dose was potentially protective for 90-day (OR 0.07; p = 0.06) but not for 1-year colectomy (OR 0.19; p = 0.16). Conclusions Bandemia and low serum albumin are independent predictors of failure of infliximab rescue therapy in acute severe ulcerative colitis. Serum albumin ≤ 2.5 g/dl and band neutrophil count ≥ 13% had a 100% positive predictive value for 90-day colectomy.
- 24 August 2019
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 26 (4) , 603-605
Is It Time For High Dose Influenza Vaccination In Inflammatory Bowel Diseases?
Immune-modifying therapy is the mainstay of treatment for moderate to severe inflammatory bowel disease (IBD) and is associated with an increased risk of infections.1, 2 A recent study found that compared with non-IBD subjects, patients with inflammatory bowel disease are at an increased risk of influenza infection.3 Vaccination against influenza is recommended in patients with IBD by several professional society guidelines and is included as a health care quality measure by the American Gastroenterology Association and Crohn’s and Colitis Foundation.4–6 However, certain immunosuppressive therapies, specifically immunomodulators and/or combinations of biologics with immunomodulators, may impact the generation of protective immune responses after influenza vaccination. Attempts to improve...
- 24 August 2019
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 26 (4) , 603-605
Is It Time For High Dose Influenza Vaccination In Inflammatory Bowel Diseases?
Immune-modifying therapy is the mainstay of treatment for moderate to severe inflammatory bowel disease (IBD) and is associated with an increased risk of infections.1, 2 A recent study found that compared with non-IBD subjects, patients with inflammatory bowel disease are at an increased risk of influenza infection.3 Vaccination against influenza is recommended in patients with IBD by several professional society guidelines and is included as a health care quality measure by the American Gastroenterology Association and Crohn’s and Colitis Foundation.4–6 However, certain immunosuppressive therapies, specifically immunomodulators and/or combinations of biologics with immunomodulators, may impact the generation of protective immune responses after influenza vaccination. Attempts to improve...
- 25 January 2019
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (Supplement) , S312-S313
P407 Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study
Our aim was to examine adverse events (AEs) during real-world usage of tofacitinib in inflammatory bowel diseases (IBD). A multi-centre cohort was assembled across six tertiary IBD centres in the US. Data on demographics, IBD-specific variables, concomitant medications and AEs (including herpes zoster [HZ], hyperlipidaemia and leukopoenia) were collected. AEs were defined as serious AE if life-threatening, resulting in a hospitalisation, disability or discontinuation of therapy. Abnormal lipid profile was defined as total cholesterol 200 mg/dl, LDL 130 mg/dl, HDL 2 test; (c) Fisher exact test) Table 1. Comparison of baseline characteristics of patients with adverse events. *Missing data in 3; **missing data in 10; (a) Mann–Whitney test; (b) χ2 test; (c) Fisher exact test)
- 25 January 2019
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 13 (Supplement) , S312-S313
P407 Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study
Our aim was to examine adverse events (AEs) during real-world usage of tofacitinib in inflammatory bowel diseases (IBD). A multi-centre cohort was assembled across six tertiary IBD centres in the US. Data on demographics, IBD-specific variables, concomitant medications and AEs (including herpes zoster [HZ], hyperlipidaemia and leukopoenia) were collected. AEs were defined as serious AE if life-threatening, resulting in a hospitalisation, disability or discontinuation of therapy. Abnormal lipid profile was defined as total cholesterol 200 mg/dl, LDL 130 mg/dl, HDL 2 test; (c) Fisher exact test) Table 1. Comparison of baseline characteristics of patients with adverse events. *Missing data in 3; **missing data in 10; (a) Mann–Whitney test; (b) χ2 test; (c) Fisher exact test)